ID: ALA2147393

Max Phase: Preclinical

Molecular Formula: C21H32N5O7P

Molecular Weight: 497.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)(C)C(=O)OCOP(=O)(C/C=C/Cn1cnc2c(N)ncnc21)OCOC(=O)C(C)(C)C

Standard InChI:  InChI=1S/C21H32N5O7P/c1-20(2,3)18(27)30-13-32-34(29,33-14-31-19(28)21(4,5)6)10-8-7-9-26-12-25-15-16(22)23-11-24-17(15)26/h7-8,11-12H,9-10,13-14H2,1-6H3,(H2,22,23,24)/b8-7+

Standard InChI Key:  XTHNWHOEXKPSKR-BQYQJAHWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 497.49

Molecular Weight (Monoisotopic): 497.2039

AlogP: 3.28

#Rotatable Bonds: 10

Polar Surface Area: 157.75

Molecular Species: NEUTRAL

HBA: 12

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 4.14

CX LogP: 3.47

CX LogD: 3.47

Aromatic Rings: 2

Heavy Atoms: 34

QED Weighted: 0.22

Np Likeness Score: -0.12

References

1. Pradère U, Roy V, Montagu A, Sari O, Hamada M, Balzarini J, Snoeck R, Andrei G, Agrofoglio LA..  (2012)  Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides.,  57  [PMID:23047229] [10.1016/j.ejmech.2012.08.042]

Source

Source(1):

• Scientific Literature